Syma Iqbal is General Practitioner at The Quay Family Healthcare. OpenAlex indexes 185 publications with 4,516 citations (h-index 34); ClinicalTrials.gov lists 23 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Syma Iqbal, MD, is General Practitioner at The Quay Family Healthcare, Torquay VIC (formerly Registrar, University Hospital Geelong / Barwon Health). The public record shows 185 publications with 4,516 citations (h-index 34), centered on Bladder / Urothelial Cancer, Hepatobiliary Cancer, Gastroesophageal Cancer. It also documents an investigator role on 23 registered clinical trials, industry payments reported by 10 companies, 2 NIH-funded awards (2006–2026).
- Most recent indexed publication: 2018 · Journal of surgical case reports
- Top research focus: Bladder / Urothelial Cancer
- 23 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 23 registered studies on ClinicalTrials.gov. The most recent:
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Sponsor: National Cancer Institute (NCI)
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Sponsor: Alliance for Clinical Trials in Oncology
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Sponsor: SWOG Cancer Research Network
Industry payments
Updated 27 Aug 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year202522 payments$36,355openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year20258 payments$14,342openpaymentsdata.cms.gov ↗
- BeiGene USA, Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.2%Kinase inhibitor44.2%Imatinib Mesylate100%Part D<11 patientsNucleoside Analog Antiviral26.9%Lonsurf100%Part D<11 patientsMetabolism & gastrointestinal
28.8%Proton pump inhibitor28.8%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Acute esophageal necrosis: a case series and its management.
Journal of surgical case reports
Case Report2018
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- LinkedIn
LinkedIn: "surgical registrar at Barwon Health" (au.linkedin.com/in/syma-iqbal-355b4b186)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →au.linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tqfhc.com.au ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tqfhc.com.au ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tqfhc.com.au ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tqfhc.com.au ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Peter Carroll, MD
University of California, San Francisco